CHMP positive opinion for two 320 mg device presentations of Bimzelx (bimekizumab) – UCB
UCB, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorization for… read more.